Clinico-laboratory research on the pharmacodynamic characteristics of Rigevidon
Korkhov, V.V.; Nikanorova, S.A.
Farmakologiia i Toksikologiia 50(1): 97-100
1987
ISSN/ISBN: 0014-8318 PMID: 3556564 Document Number: 287190
The effect of the new combined oral contraceptive agent Rigevidon on the hypothalamo-hypophyseal-ovarian system was studied in 50 women (age not specified). Rigevidon was given for 21 days with subsequent 7-day interval. Duration of administration was 10-12 cycles. Functional state of the ovaries and gonadotropic function of the pituitary gland was evaluated by measuring the blood levels of estradiol, progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). During Rigevidon administration in doses producing the contraceptive effect, all women showed the monophasic type of basal temperature. FSH levels on days 7-9 and 20-23 of cycle 3, 6 and 10-12 did not differ significantly from those in controls; there was a 2.8 times decrease FSH levels on days 14-16 of cycle 3 and a 3.8 times decrease on days 14-16 of cycle 10-12. Marked decrease in LH levels was observed on days 14-16 of cycle (5 times) and during the 6th cycle (9.2 times). Significant decrease in estradiol levels was recorded on days 7-9 and 14-16 of cycle 3,6 and 10-12. Progesterone levels were decreased significantly on days 7-9 and 20-23 of cycle 3, 6 and 10-12; significant decrease in progesterone levels on days 14-16 was observed only during cycle 3. Prolonged administration of Rigevidon (10-12 cycles) produced no changes in prolactin secretion. After cessation of Rigevidon administration, the LH and estradiol levels were decreased only on days 14-16 of cycle 1. The test with LH releasing hormone (100 mc) on days 12-14 after Rigevidon cessation showed normal sensitivity of the pituitary gland to hypothalamic stimulation. The results of this study indicate that the contraceptive effect of Rigevidon is associated with inhibition of ovulation and cyclic secretion of FSH and LH.